English 简体中文
产品
文章
搜索
搜索
首页 ∷ 试剂 ∷ 阿拉丁 ∷ C127870 卡非佐米 ,≥99%
当前位置：
C127870 卡非佐米 ,≥99%

C127870 卡非佐米 ,≥99%

0.00
0.00
  
商品描述

基本信息

产品名称卡非佐米
英文名称Carfilzomib
别名卡非佐米;Proteasomel抑制剂
英文别名PR 171;PR171;PR-171; (alphaS)-alpha-[(4-Morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-phenylalaninamide
规格或纯度≥99%
运输条件超低温冰袋运输
生化机理Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant anti-tumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drμg-drμg interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 min, was evaluated in patients with solid tumors or MM. The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a first-in-class, reversible proteasome inhibitor, for relapsed/refractory multiple myeloma (MM). Carfilzomib induced a dose- and time-dependent inhibition of proliferation, ultimately leading to apoptosis. Carfilzomib showed increased efficacy compared with bortezomib and was active against bortezomib-resistant MM cell lines and samples from patients with clinical bortezomib resistance. Carfilzomib has entered in a Phase II clinical trial in the treatment of multiple myeloma

一般描述

Carfilzomib (PR-171)是一种不可逆proteasome抑制剂，IC50为<5 nM，在体外优先抑制β5亚基的ChT-L活性，对PGPH和T-L活性很弱或没有作用。Proteasomel抑制剂,epoxomicin的类似物


Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.
Proteasome inhibitor, analog of epoxomicin

相关属性

CAS编号868540-17-4
溶解性DMSO 50 mg/mL Water <1 mg/mL Ethanol <1 mg/mL
储存温度-20°C储存
分子量719.91
分子式C40H57N5O7
品牌阿拉丁
备注如果有可能，您尽量在同一天配置溶液，并在当天使用完它。但是，如果您需要预先配制储备溶液，我们建议您将溶液等份保存在-20°C的密封小瓶中。通常，它们最多可以使用一个月。在使用前和打开样品瓶之前，我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度，用法和处理的建议吗？请访问我们的常见问题（FAQ）页面以获取更多详细信息。
PubChem CID11556711